Friday, 23 Aug 2019

You are here

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

A similar trial was published in JAMA in 2008 wherein obese children with HTN and a uric acid (SUA) level > 6.0 mg/dl were treated with either placebo or allopurinol 400 mg/d. At 4 weeks the SUA dropped from a mean of 7 mg/dl to 4.2 mg/dl with allopurinol and 67% of the kids normalized their hypertension (vs only 3% with placebo). These data suggested the aggressive ULT would positively affect the kidney and resultant hypertension.

In the EULAR crossover trial, presented by Gaffo et al (OP0208), allopurinol or PBO was given to 82 young adults with prehypertension or stage 1 hypertension. It failed to significantly lower blood pressure but succeeded in significantly improving endothelial function as measured by increased flow-mediated arterial dilation (FMD).

While the latter findings are encouraging, the inability to lower BP was disappointing.  This trial differs from the aforementioned trial by age (adolescents vs young adults), obesity, or other enrollment criteria (eg, the level of SUA).

The authors of this trial noted that a BP-lowering effect with allopurinol was strongest in people who entered the study with the highest serum urate levels, greater than 6.5 mg/dL.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

Excess Non-CV Mortality Persists in Gout

Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.

Despite Gout Numbers and Flares, Allopurinol is Underutilized

A population-based survey from South Australia shows that gout flares are common in the community and have a significant effect on health-related quality of life (HRQoL), yet there is significant undertreatment of gout, even in those on current allopurinol.